006280 — GC Biopharma Income Statement
0.000.00%
Last trade - 00:00
- KR₩2tn
- KR₩3tn
- KR₩2tn
- 18
- 35
- 98
- 49
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | — | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,357,117 | 1,504,115 | 1,537,826 | 1,711,313 | 1,626,644 |
Cost of Revenue | |||||
Gross Profit | 372,173 | 440,627 | 520,593 | 581,804 | 484,633 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1,329,202 | 1,403,645 | 1,455,901 | 1,589,582 | 1,592,208 |
Operating Profit | 27,916 | 100,471 | 81,925 | 121,731 | 34,436 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1,163 | 104,474 | 172,559 | 85,728 | -27,135 |
Provision for Income Taxes | |||||
Net Income After Taxes | -6,309 | 89,108 | 136,950 | 69,415 | -19,809 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -3,638 | 81,049 | 123,212 | 65,453 | -26,632 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -3,638 | 81,049 | 123,212 | 65,453 | -26,632 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 598 | 3,323 | 10,309 | 2,850 | -2,167 |
Dividends per Share |